Bellevue Life Sciences Acquisition Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, net income was USD 0.489952 million compared to net loss of USD 0.021136 million a year ago. Basic earnings per share from continuing operations was USD 0.06 compared to basic loss per share from continuing operations of USD 0.01 a year ago. Diluted earnings per share from continuing operations was USD 0.03 compared to diluted loss per share from continuing operations of USD 0.01 a year ago.